About US
Contact us
-
Roche ushers early lung cancer into immunotherapy era with Tecentriq FDA approval. Will doctors follow?Roche’s Tecentriq has ushered in a new era, offering the firstimmunotherapy option fornon-small cell lung cancer (NSCLC) patients right after tumor surgery. But doctors appear reluctant to use it for2021/10/18
-
The energy switch: Big Pharma harnesses sun, wind and water in quest for a low-carbon futureAlongside collaborative robots and automated guided vehicles, Amgen has carved out space for solar panels at its upcoming smart factory in New Albany, Ohio. The company’s $550 million facility-to-be2021/10/18
-
Johnson & Johnson wins FDA panel backing for a second dose of its COVID shot but don’t call it a ‘booster’Over the last year, the Johnson & Johnson COVID-19 vaccine has been commonly referred to as a single-shot alternative to the two-dose regimens of mRNA vaccines from Pfizer-BioNTech and Moderna. B2021/10/15
-
Amgen's latest Lumakras data in KRAS cancer underscore the bumpy road for combo strategy: analystWith Lumakras the first drug specifically approved for KRAS-mutated cancer, Amgen is examining various combination options to expand its reach. But new data underline the difficulty in finding the ri2021/10/13
-
Sanofi, GSK, Pfizer and Boehringer must face Zantac class-action lawsuits, court rulesEven after the global Zantac recalls of 2019 and 2020 and the associated controversy, the courtroom saga over the medicine's risk is just getting started. This week, branded drugmakers GlaxoSmithKlin2021/10/13
-
GlaxoSmithKline to leave landmark global HQ after split-up as consumer health business plots £120M new homeGlaxoSmithKline isn’t just making changes with itsU.S. operations. The company is nowexploring a new location for its global headquarters amid a historic business revamp. GSK will leave i2021/10/11
-
Viatris to close former Novartis site in California in January, lay off 75Viatris has been busy with cost cuts over the last year, including shuttering a plant in West Virginia that had served as a staple of its community.Now, a former Novartis plant in California—which My2021/10/11
-
AbbVie pressures Biohaven in migraine prevention with FDA approval for its CGRP blockbuster-to-be QuliptaTuesday, AbbVie said the FDA hasgreen-lightedits Qulipta, or atogepant, for prevention of episodic migraine. The go-ahead follows the landmark approval of Biohaven’s Nurtec ODT as the first oral anti2021/9/30
-
Merck's reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom: analystsMerck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-oncology megablockbuster Keytruda, bu2021/9/30
-
CDMO Lonza strikes deal with Allarity Therapeutics to manufacture cancer drug candidate dovitinibAllarity Therapeutics has worked diligently to develop Novartis’ failed cancer drug dovitinib. Now, as the Danish biotech anticipates the drug’s approval for metastatic renal cell carcinoma, it has l2021/9/27